Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets
NCT ID: NCT01324336
Last Updated: 2021-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2011-07-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy
NCT03920813
Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid
NCT01906671
The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China
NCT04228393
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02642965
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02556346
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
4-17 years, receiving 6-MP
6-Mercaptopurine
75 mg/m2/dose/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
6-Mercaptopurine
75 mg/m2/dose/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Received methotrexate or folate supplement within the last 24 hours
* Pregnant or lactating females
* Inability to swallow a pill
* Hemoglobin less or equal to 8 gm/dl
* Presence of significant co-morbid illness that makes child ineligible as deemed by the investigator
* Weight \< or = 16 kg
4 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Midwest Cancer Alliance
UNKNOWN
Children's Mercy Hospital Kansas City
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathleen A Neville, MD, MS
Role: PRINCIPAL_INVESTIGATOR
The Children's Mercy Hospitals and Clinics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Children's Mercy Hospital
Kansas City, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6-MP pharmacokinetic 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.